Keith J. Kendall's most recent trade in Femasys Inc was a trade of 17,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 14, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Femasys Inc | Keith J. Kendall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2023 | 17,000 | 17,000 | - | - | Stock Option (Right to Buy) | |
| Aquestive Therapeutics Inc | Keith J. Kendall | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 375,000 | 375,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Aquestive Therapeutics Inc | Keith J. Kendall | Director, CEO and President | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Aug 2021 | 1,000 | 636,149 (1%) | 0% | - | Common Stock | |
| Aquestive Therapeutics Inc | Keith J. Kendall | Director, CEO and President | Gift of securities by or to the insider at price $ 0.00 per share. | 26 Aug 2021 | 1,000 | 1,000 (0%) | 0% | - | Common Stock | |
| Aquestive Therapeutics Inc | Keith J. Kendall | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2021 | 250,000 | 250,000 | - | - | Non-Qualified Stock Option (right to buy) |